Biogen, Elan seek okay for first-line Tysabri use in MS

LONDON Wed Jan 16, 2013 3:42pm IST

Related Topics

Stocks

   

LONDON (Reuters) - Biogen Idec and Elan have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis, a move that could boost sales of the drug.

Demand for Tysabri has been curtailed due to concerns over its association with a potentially fatal infection known as progressive multifocal leukoencephalopathy, or PML, which is caused by the JC virus.

Now, however, there is a test for the virus to predict if patients are at risk of developing PML, opening the possibility that Tysabri could be used more widely and at an earlier stage of treatment.

Biogen and Elan said on Wednesday they had submitted applications to the U.S. Food and Drug Administration and the European Medicines Agency seeking approval for first-line use in patients with relapsing forms of multiple sclerosis (MS) who have tested negative for antibodies to the JC virus.

The JC virus is generally harmless, but in people with weakened immune systems, such as those using immune system-suppressing drugs like Tysabri, it can lead to an increased chance of developing PML.

Tysabri use is currently limited to between 10 and 12 percent of treated MS patients, due to the risk of PML, and analysts said the hoped-for wider approval would improve uptake and send a positive signal to doctors.

Berenberg analysts said Tysabri's share of the MS market could increase to about 15 percent by 2015, representing sales of $2.9 billion, while today's share price for Elan implied peak sales of only some $2 billion.

Tysabri was briefly pulled from the market over PML concerns - but it was considered to be so effective, compared with other available treatments, that MS patients argued the risk was worth taking and demanded its return.

Health regulators bowed to the pressure and allowed the drug's relaunch with restrictions.

"A first-line approval would allow people with MS access to a highly efficacious treatment earlier in the course of the disease, potentially leading to better outcomes," said Alfred Sandrock, Biogen's chief medical officer.

"This is an important consideration for people with MS who may want or need more efficacy."

Both the U.S. and European regulators are expected to decide on the applications for first-line use later this year.

(Reporting by Ben Hirschler; Editing by Louise Heavens)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

Eat That Carrot

Eat That Carrot

Start early for a lifetime of good vision and healthy eyes.  Full Article 

Triggering Violence

Triggering Violence

What makes hospital patients turn violent?  Full Article 

Corruption Issue

Corruption Issue

After China, GlaxoSmithKline faces pressure for change.  Full Article 

Good Or Bad?

Good Or Bad?

Study of smoking cancer patients fuels e-cigarette debate.  Full Article 

Much-Needed

Much-Needed

Allowing blood donations from gay men could help save over a million lives: U.S. study.  Full Article 

Not Aware

Not Aware

Kidney patients know little about transplant benefits.  Full Article 

Get Up

Get Up

Sedentary lifestyle linked to depression.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage